Summary of Significant Accounting Policies - Narrative (Details)	1 Months Ended							12 Months Ended
	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2018 shares	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2023 USD ($) segment shares	Dec. 31, 2022 USD ($)	Sep. 30, 2018
Accumulated deficit								$ 254,370,827	$ 209,153,659
Net loss								46,833,186	43,862,197
Cash, cash equivalents and short term investments								$ 2,400,000
Number of operating segments | segment								1
FDIC insured amount								$ 250,000	250,000
Uninsured cash balance								$ 0	$ 7,800,000
Dividend yield								0.00%	0.00%
Revenue								$ 6,994,838	$ 370,176
Estimated fair value of 3% ANTHIM earnout								1,720,000
Deferred revenue								2,400,000	1,600,000
Elusys Therapeutics business unit | Held for sale
Contingent consideration receivable, off-market issuance of a Convertible Note								300,000
Estimated fair value of 3% ANTHIM earnout								1,700,000
Shattuck
License fee received							$ 50,000
Deferred revenue								$ 30,000.00	$ 40,000.00
Proceeds from milestone payment		$ 100,000
Pelican Therapeutics, Inc.
Percentage of non-controlling interest acquired								15.00%	15.00%
Scorpius Biomanufacturing
Percentage of non-controlling interest acquired								6.00%	6.00%
Minimum
Estimated useful lives								3 years
Maximum
Estimated useful lives								8 years
Sales revenue net | Geographic Concentration Risk | Canada
Concentration risk, percentage									94.00%
Sales revenue net | Geographic Concentration Risk | United States
Concentration risk, percentage								100.00%	6.00%
Lab equipment
Estimated useful lives								5 years
Computers
Estimated useful lives								3 years
Furniture and fixtures and vehicles
Estimated useful lives								8 years
Common stock warrants
Warrants exchanged | shares								0
Heat I
Ownership interest in subsidiary				100.00%
Pelican Therapeutics, Inc.
Ownership interest in subsidiary				85.00%				85.00%	85.00%	80.00%
Scorpius Therapeutics, Inc.
Ownership interest in subsidiary								94.00%
Heat I, Inc. and Pelican
Shares issued in acquisition | shares				35,000
Pelican Therapeutics, Inc.
Contingent consideration liability, written off									$ 3,300,000
Pelican Therapeutics, Inc. | Grant and contract revenue
Revenue	$ 1,500,000							$ 15,200,000
Remaining grant amount receivable								$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue						$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue					$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue			$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant							$ 15,200,000